Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IDL Diagnostics ABOSTO:IDLDX -3.67%55 3-1 Month Momentum % is -10.42% as of Sep. 01, 2026. GuruFocus rates OSTO:IDLDX with a GF Score™ of 55/100 and a GF Value™ of kr0.54 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 214 Medical Diagnostics & Research companies, IDL Diagnostics AB ranks worse than 64.95% on this metric.
3-1 Month Momentum % is the total return of the stock from 3-month ago to 1-month ago. As of today (2026-09-01), IDL Diagnostics AB's 3-1 Month Momentum % is -10.42%.
The industry rank for IDL Diagnostics AB's 3-1 Month Momentum % or its related term are showing as below:
OSTO:IDLDX's 3-1 Month Momentum % is ranked worse than 64.95% of 214
companies
in the Medical Diagnostics & Research industry
Industry Median: -3.525
vs OSTO:IDLDX: -10.42
IDL Diagnostics AB (OSTO:IDLDX) 3-1 Month Momentum % Explanation
Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 3-1 Month Momentum % measures the total return to a stock over the past three months, but ignores the previous month.
The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.
IDL Diagnostics AB 3-1 Month Momentum % Related Terms
OSTO:IDLDX vs TMO, DHR, NTRA: 3-1 Month Momentum % Comparison
For the Diagnostics & Research subindustry, IDL Diagnostics AB's 3-1 Month Momentum %, along with its competitors' market caps and 3-1 Month Momentum % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
IDL Diagnostics AB 3-1 Month Momentum % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, IDL Diagnostics AB's 3-1 Month Momentum % distribution charts can be found below:
* The bar in red indicates where IDL Diagnostics AB's 3-1 Month Momentum % falls into.
IDL Diagnostics AB (OSTO:IDLDX) 3-1 Month Momentum % Calculation
3-1 Month Momentum % is calculated as following:
3-1 Month Momentum %
=
( Price 1-month ago
/
Price 3-month ago
- 1 )
*
100 %
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDL Diagnostics AB (OSTO:IDLDX) has a 3-1 Month Momentum % of -10.42% as of Sep. 01, 2026. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on IDL Diagnostics AB and its competitors. According to the industry distribution chart, IDL Diagnostics AB ranks #139 out of 214 companies in the Medical Diagnostics & Research industry, placing it in the top 65%.
Is IDL Diagnostics AB's 3-1 Month Momentum % too high?
IDL Diagnostics AB's current 3-1 Month Momentum % is -10.42%. Based on the distribution chart, IDL Diagnostics AB ranks #139 out of 214 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, IDL Diagnostics AB has a GF Score™ of 55/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does IDL Diagnostics AB's 3-1 Month Momentum % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, IDL Diagnostics AB ranks #139 out of 214 companies for 3-1 Month Momentum %. This places IDL Diagnostics AB in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-1 Month Momentum % for a Medical Diagnostics & Research company?
A good 3-1 Month Momentum % depends on the Medical Diagnostics & Research industry context. However, 3-1 Month Momentum % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-1 Month Momentum % mean?
A high 3-1 Month Momentum % can signal that a stock is expensive relative to its fundamentals. 3-1 Month Momentum measures the total return of the stock from 3-month ago to 1-month ago. View historical data on IDL Diagnostics AB and its competitors. IDL Diagnostics AB's current 3-1 Month Momentum % is -10.42%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is IDL Diagnostics AB stock overvalued right now?
Based on GuruFocus' analysis, IDL Diagnostics AB (OSTO:IDLDX) is currently considered Modestly Undervalued. The stock's GF Value™ is kr0.54, compared to a current price of kr0.39 — trading 27% below its estimated fair value. The current 3-1 Month Momentum % is -10.42%. IDL Diagnostics AB's overall GF Score™ is 55/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-1 Month Momentum % calculated?
3-1 Month Momentum % is calculated from a company's financial statements. For IDL Diagnostics AB (OSTO:IDLDX), the current 3-1 Month Momentum % is -10.42% as of Sep. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is IDL Diagnostics AB (OSTO:IDLDX) Overvalued in 2026?
Based on GuruFocus' analysis, IDL Diagnostics AB stock appears to be undervalued.
The current stock price of kr0.39 is trading 27% below its estimated GF Value™ of kr0.54.
GuruFocus considers IDL Diagnostics AB to be Modestly Undervalued.
Key valuation signals for OSTO:IDLDX:
3-1 Month Momentum %: -10.42%
GF Value™: kr0.54 vs. price of kr0.39 (27% below fair value)
No single metric tells the full story. See the OSTO:IDLDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
IDL Diagnostics AB is a Swedish company that develops and markets blood and urine sample tests. It specializes in oncology and bacteriology. The company has a broad product portfolio, is used in healthcare, and is established in various markets. In oncology, IDL Diagnostics uses various biomarkers, TK1 and cytokeratins, to support the treatment of cancers such as breast, prostate, and bladder cancers.
55GF Score
Get the complete analysis for OSTO:IDLDX
3-1 Month Momentum % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:IDLDX has been successfully added to your 
